 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || NPX267 / NextPoint
Trial completion date, Trial primary completion date: A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7 (clinicaltrials.gov) - Dec 31, 2023
P1, N=131, Recruiting, Sponsor: NextPoint Therapeutics, Inc.
- | NPX267 / NextPoint
Phase classification: A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7 (clinicaltrials.gov) - Nov 15, 2023
P1, N=131, Recruiting, Sponsor: NextPoint Therapeutics, Inc.
Phase classification: P1a/1b --> P1
- NPX267 / NextPoint
A Phase 1a/1b, dose-escalation/dose-expansion study of NPX267 in subjects with solid tumors known to express HHLA2 (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_973;
4 Key eligibility criteria include histologic diagnosis of tumor types known to express HHLA2, refractory metastatic or locally advanced disease and the absence of autoimmune disease or history of colitis or pneumonitis. HHLA-2 expression will be assessed by immunohistochemistry from archival tissue and fresh biopsies to assess correlation with pharmacodynamic and clinical activity to determine the potential use of HHLA2 expression as a prospective selection marker.
- ||| NPX267 / NextPoint
Enrollment open: A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7 (clinicaltrials.gov) - Sep 21, 2023
P1a/1b, N=131, Recruiting, Sponsor: NextPoint Therapeutics, Inc.
HHLA-2 expression will be assessed by immunohistochemistry from archival tissue and fresh biopsies to assess correlation with pharmacodynamic and clinical activity to determine the potential use of HHLA2 expression as a prospective selection marker. Not yet recruiting --> Recruiting
- | NPX267 / NextPoint
New P1 trial: A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7 (clinicaltrials.gov) - Jul 25, 2023
P1a/1b, N=131, Not yet recruiting, Sponsor: NextPoint Therapeutics, Inc.
- NPX267 / NextPoint
NPX267, a first-in-class monoclonal antibody targeting KIR3DL3, blocks HHLA2-mediated immunosuppression and potentiates T and NK cell-mediated antitumor immunity (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_824;
Conclusions Collectively, these data demonstrate that the KIR3DL3-HHLA2 pathway is a novel immune checkpoint axis that facilitates tumor escape by attenuating both innate and adaptive antitumor immune responses. NPX267, a first-in-class KIR3DL3 blocking antibody, potentiates anti-tumor immunity against HHLA2 + tumors and may represent a promising approach to treat certain cancers.